Status:
COMPLETED
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia
Lead Sponsor:
Biogen
Conditions:
Schizophrenia
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
To evaluate the safety and tolerability of multiple, ascending doses of PF-04958242 administered orally to psychiatrically stable subjects with schizophrenia receiving antipsychotic and adjunctive med...
Detailed Description
This study was previously posted by Pfizer, Inc. Sponsorship of the trial was transferred to Biogen.
Eligibility Criteria
Inclusion
- Psychiatrically stable subjects with schizophrenia
- Evidence of stable schizophrenia symptomatology ≥ 3 months
- Score on MCCB Letter-number span + Spatial span subtest \< 40.
Exclusion
- History of seizures or of a condition with risk of seizures
- History of abnormal EEG.
- Pregnant or nursing females, and women of child bearing potential
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01518894
Start Date
November 1 2011
End Date
March 1 2012
Last Update
November 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Long Beach, California, United States, 90806